Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE Data in Diabetic Macular Edema in Ophthalmology Retina - Seite 2
Title: Post Hoc Analysis of Clinical Suprachoroidal Injection Experience Across Indications
Author: Chris Henry; faculty sponsor Amy Schefler; Cherry Wan; Barry Kapik; Colette Hall; Thomas Ciulla
Conclusions: To date, this is the most robust aggregate dataset of clinical suprachoroidal injections with mounting evidence pointing to the potential
reliability and consistency of the procedure. The results from the retrospective analysis demonstrated the robustness of the suprachoroidal injection regardless of indications. The two needle
length options successfully accommodated for anatomical variations across patients.
Title: Suprachoroidal Delivery of Small Molecule Suspensions and Nanoparticles
Authors: Judy Kim; Viral Kansara; Thomas Ciulla
Conclusions: Delivery of small molecule suspensions may provide targeted, well-tolerated, and long-acting delivery of a wide variety of pharmacologic agents, including
corticosteroids, tyrosine kinase inhibitors (TKIs), and complement inhibitors to the RPE, sclera and choroid. Preclinical models for these compounds were promising and based on the favorable
clinical results of a small molecule corticosteroid for macular edema associated with noninfectious uveitis, further testing is warranted for these other molecules. Additionally, suprachoroidal
delivery of DNA nanoparticle-based gene has potential as an office-based retinal gene therapy; and further testing is warranted.
Lesen Sie auch
Title: Suprachoroidally delivered non-viral DNA nanoparticles transfect chorioretinal cells in non-human primates
and rabbits
Authors: Nancy Holekamp; Viral Kansara; Thomas Ciulla
Conclusions: Suprachoroidal injections of DNA Nanoparticles may address several unmet needs in ocular gene delivery. DNA nanoparticles are relatively non-immunogenic compared to
viral vector-based gene therapy, and suprachoroidal injection facilitates the potential for office-based repeat dosing with fewer safety risks compared to subretinal injection via pars plana
vitrectomy surgery. In addition, DNA nanoparticles can transfer genes beyond the capacity of viral vectors, including those in common inherited retinal diseases (IRDs) such as Stargardt disease and
Usher syndrome. Additional research evaluating suprachoroidal injection in non-human primates and delivery of a therapeutic transgene is needed.